Drug intelligence / Profile preview

ADPS

Development stage: Phase 2
Lead developer: Taro
Modality: Small Molecules
Administration: Topical

Overview

ADPS is a small molecule drug initially developed by Taro Pharmaceuticals U.S.A. for the treatment of skin and musculoskeletal diseases, with a primary focus on acne vulgaris. Its molecular formula is C12H19NO4S, and it has been evaluated in at least one completed Phase 2 clinical trial for acne vulgaris. The precise mechanism of action and molecular target are not specified in the available data. As of January 2025, its highest global R&D status is listed as "Pending," indicating that it has not yet received regulatory approval or advanced beyond Phase 2 trials[2].

Beyond the preview

Go deeper on ADPS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADPS.

Explore the full profile